Physician profile
Mohanad Suede
NPI 1720436843
$6,478.46
in general payments reported to CMS, 2019-2025
23 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $555 · 2021: $390 · 2022: $499 · 2023: $1,114 · 2024: $1,677 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,607 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,606.89 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,389.26 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $964.88 | 2020-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $804.72 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $382.77 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $298.50 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $280.64 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $229.68 | 2023-2025 | Dupixent |
| Genzyme Corporation | $229.33 | 2023-2025 | |
| Madrigal Pharmaceuticals | $160.07 | 2025 | Rezdiffra |
| Celgene Corporation | $143.36 | 2023-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $121.35 | 2019 | |
| Janssen Scientific Affairs, LLC | $118.50 | 2022 | |
| Phathom Pharmaceuticals, INC. | $103.29 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $77.49 | 2023-2024 | Rebyota, Clenpiq |
| Intercept Pharmaceuticals, INC. | $38.52 | 2019-2023 | Ocaliva |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $22.81 | 2023 | Terlivaz |
| Qol Medical, LLC | $19.31 | 2023 | Sucraid |
| Capsovision, INC. | $19.30 | 2024 | Capsocam Plus |
| Nestle Healthcare Nutrition INC. | $16.46 | 2020 | |
| Redhill Biopharma INC. | $16.44 | 2023 | Talicia |
| Pfizer INC. | $14.26 | 2024 | |
| Merck Sharp & Dohme LLC | $14.13 | 2023 | Dificid |
| Vivus LLC | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohanad Suede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.